The combined company will be called Pfizer plc. The company will maintain its global headquarters in New York but its key executive offices in Ireland. The deal is expected to close in the second half of 2016. According to Pfizer chief executive Ian Read in a statement, the world will have to expect “continued discovery and development of new innovative medicines for patients.” At this time Pfizer has leading products in seven high growth therapeutic areas. This includes drugs like the cholesterol-fighting Lipitor and erectile dysfunction medication Viagra.